Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Future Oncol ; 20(3): 131-143, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-37807952

RESUMEN

Aim: To compare the effectiveness of in-class transition to all-oral ixazomib-lenalidomide-dexamethasone (IRd) following parenteral bortezomib (V)-based induction versus continued V-based therapy in US oncology clinics. Patients & methods: Non-transplant eligible patients with newly diagnosed multiple myeloma (MM) receiving in-class transition to IRd (N = 100; US MM-6), or V-based therapy (N = 111; INSIGHT MM). Results: Following inverse probability of treatment weighting, overall response rate was 73.2% with IRd versus 57.5% with V-based therapy (p < 0.0001). Median duration of treatment was 10.8 versus 5.3 months (p < 0.0001). Overall, 18/24% of patients discontinued IRd/V-based therapy due to adverse events. Conclusion: IRd after V-based induction was associated with significantly improved overall response rate and duration of treatment than continued V-based combination therapy. Clinical Trial Registration: US MM-6: NCT03173092; INSIGHT MM: NCT02761187 (ClinicalTrials.gov).


Asunto(s)
Mieloma Múltiple , Humanos , Mieloma Múltiple/diagnóstico , Mieloma Múltiple/tratamiento farmacológico , Bortezomib/efectos adversos , Lenalidomida/uso terapéutico , Dexametasona , Glicina , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Compuestos de Boro/efectos adversos
2.
Clin Lymphoma Myeloma Leuk ; 20(11): e910-e925, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-32912820

RESUMEN

BACKGROUND: The ongoing US MM-6 study is investigating in-class transition (iCT) from parenteral bortezomib-based induction to all-oral IRd (ixazomib-lenalidomide-dexamethasone) with the aim of increasing proteasome inhibitor (PI)-based treatment adherence and duration while maintaining patients' health-related quality of life (HRQoL) and improving outcomes. PATIENTS AND METHODS: US community sites are enrolling non-transplant-eligible patients with newly diagnosed multiple myeloma (MM) with no evidence of progressive disease after 3 cycles of bortezomib-based therapy to receive IRd (up to 39 cycles or until progression or toxicity). The patients use mobile or wearable digital devices to collect actigraphy (activity and sleep) data and electronically complete HRQoL, treatment satisfaction and medication adherence questionnaires. The primary endpoint is progression-free survival. The key secondary endpoints include response rates and therapy duration. RESULTS: At the data cutoff, 84 patients had been treated (median age 73 years; 44% aged ≥ 75 years; 49% men; 15% Black or African American; and 10% Hispanic or Latino). Of the 84 patients, 62% were continuing therapy. The mean duration of total PI therapy was 10.1 months and for the IRd regimen was 7.3 months. With an 8-month median follow-up, the 12-month progression-free survival rate was 86% (95% confidence interval, 73%-93%) from both the start of bortezomib-based treatment and the start of IRd. The overall response rate was 62% (complete response, 4%; very good partial response, 25%; partial response, 33%) after bortezomib-based induction and 70% (complete response, 26%; very good partial response, 29%; partial response, 15%) after iCT. The IRd safety profile was consistent with previous clinical trial data, and HRQoL and treatment satisfaction were maintained. CONCLUSION: The patients included in the US MM-6 study are representative of the real-world US MM population. The use of iCT might permit prolonged PI-based therapy with promising efficacy, without impacting patients' HRQoL or treatment satisfaction.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Compuestos de Boro/uso terapéutico , Bortezomib/uso terapéutico , Glicina/análogos & derivados , Mieloma Múltiple/tratamiento farmacológico , Inhibidores de Proteasoma/uso terapéutico , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Compuestos de Boro/farmacología , Bortezomib/farmacología , Femenino , Glicina/farmacología , Glicina/uso terapéutico , Humanos , Masculino , Mieloma Múltiple/mortalidad , Mieloma Múltiple/patología , Supervivencia sin Progresión , Inhibidores de Proteasoma/farmacología , Análisis de Supervivencia , Resultado del Tratamiento
3.
In Vivo ; 28(6): 1131-4, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25398811

RESUMEN

BACKGROUND: The present study evaluated interleukin-6 (IL6) as a predictor of mortality in patients and sepsis with acute kidney injury (AKI) receiving sustained low-efficiency dialysis (SLED) and antibiotic therapy. PATIENTS AND METHODS: Seven patients with sepsis receiving antibiotics and SLED for AKI were studied. Blood was obtained at baseline prior to SLED and antibiotics, during SLED, and then after stopping SLED. IL6 concentrations were measured using an enzyme-linked immunosorbent assay (ELISA). RESULTS: Mean plasma IL6 concentrations ranged between 700 and 900 pg/ml for the first 8 h after starting SLED but was significantly lower after discontinuation of SLED (200-250 pg/ml) (p=0.0044). Three out of seven patients survived to be discharged from the hospital and all three had significantly lower concentrations of IL6 during the first 8 h compared to those who died in the hospital (p<0.0001). CONCLUSION: The combination of SLED and antibiotic therapy was unable to lower the initial high plasma IL6 concentrations, and high initial IL6 concentrations predicted in-hospital mortality.


Asunto(s)
Lesión Renal Aguda/sangre , Lesión Renal Aguda/etiología , Interleucina-6/sangre , Sepsis/sangre , Sepsis/complicaciones , Lesión Renal Aguda/mortalidad , Lesión Renal Aguda/terapia , Anciano , Antibacterianos/uso terapéutico , Biomarcadores , Femenino , Mortalidad Hospitalaria , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Diálisis Renal , Sepsis/tratamiento farmacológico , Sepsis/mortalidad , Factores de Tiempo , Resultado del Tratamiento
4.
Crit Care Med ; 39(3): 560-70, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21221000

RESUMEN

OBJECTIVE: To address issues of antibiotic dosing during sustained low-efficiency dialysis by using available pharmacokinetic data, intermittent and continuous renal replacement therapy dialysis guidelines, and our experience with sustained low-efficiency dialysis. DATA RESOURCES: Published clinical trials, case reports, and reviews of antibiotic dosing in humans during sustained low-efficiency dialysis. DATA EXTRACTION: A search of electronic databases (MEDLINE, PubMed, and Ovid) was conducted by using key words of extended daily dialysis, sustained low-efficiency dialysis, antibiotics, antimicrobial agents, and pharmacokinetics. MEDLINE identified 32 sustained low-efficiency dialysis articles, and PubMed identified 33 articles. All papers describing antibiotic clearance prospectively in patients were considered for this article. DATA SYNTHESIS: We identified nine original research articles and case reports that determined the impact of sustained low-efficiency dialysis on antibiotic clearance in patients. The blood and dialysate flow rates, duration of dialysis, type of filter, and the pharmacokinetic parameters were extracted from each article. If multiple articles on the same drug were published, they were compared for consistency with the aforementioned dialysis parameters and then compared with forms of continuous renal replacement therapy. Antibiotic clearance by sustained low-efficiency dialysis was determined to be similar or higher than continuous renal replacement therapy therapies. The estimated creatinine clearance during sustained low-efficiency dialysis was approximately 60 mL/min to 100 mL/min depending on the blood and dialysate flow rates and the type of filter used. CONCLUSIONS: The potential for significant drug removal during an 8-hr-or-longer sustained low-efficiency dialysis session is evident by the limited number of studies available. Because significant amounts of drug may be removed by sustained low-efficiency dialysis combined with altered pharmacokinetic variables in critically ill patients, the risk for suboptimal drug concentrations and pharmacodynamics must be considered. Appropriate dose and calculation of dosing intervals is essential to provide adequate antibiotic therapy in these patients. It is recommended that institutions who utilize sustained low-efficiency dialysis establish dosing guidelines for all pharmacists and physicians to follow to provide consistent delivery of antibiotics at adequate concentrations.


Asunto(s)
Antibacterianos/administración & dosificación , Cuidados Críticos/métodos , Diálisis Renal , Acetamidas/administración & dosificación , Acetamidas/farmacocinética , Aminoglicósidos/administración & dosificación , Aminoglicósidos/farmacocinética , Antibacterianos/farmacocinética , Carbapenémicos/administración & dosificación , Carbapenémicos/farmacocinética , Daptomicina/administración & dosificación , Daptomicina/farmacocinética , Equinocandinas/administración & dosificación , Equinocandinas/farmacocinética , Fluoroquinolonas/administración & dosificación , Fluoroquinolonas/farmacocinética , Humanos , Linezolid , Oxazolidinonas/administración & dosificación , Oxazolidinonas/farmacocinética , Diálisis Peritoneal Ambulatoria Continua/efectos adversos , Diálisis Peritoneal Ambulatoria Continua/métodos , Diálisis Renal/efectos adversos , Diálisis Renal/métodos , Insuficiencia Renal/terapia , Vancomicina/administración & dosificación , Vancomicina/farmacocinética
5.
Neurorehabil Neural Repair ; 23(5): 422-8, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19276293

RESUMEN

BACKGROUND: To assess upper extremity (UE) capabilities following stroke, the Wolf Motor Function Test (WMFT) measures time to complete 15 UE tasks and 2 strength tasks, but takes 30 to 45 minutes for the clinician to complete. OBJECTIVE: In an effort to streamline the WMFT, this study evaluated the association between the magnitude of improvement on any timed task of the WMFT and the change score on all other tasks among participants in the Extremity Constraint Induced Therapy Evaluation (EXCITE) trial. METHODS: This association was evaluated using regression methods according to chronicity and controlling for key covariates (functional level, gender, concordance) for log mean WMFT scores. RESULTS: After controlling for covariates, 6 tasks (hand to table [front], hand to box [front], reach and retrieve, lift can, lift pencil, and fold towel) influenced the overall WMFT score for survivors meeting EXCITE criteria and treated within 3 to 9 months poststroke. Six different tasks (extend elbow weight, hand to box [front], lift can, lift pencil, turn key in lock, and fold towel) influenced the overall WMFT score for those receiving constraint-induced movement therapy (CIMT) 1 year later. The importance of certain tasks relative to others may best represent overall UE function, but this streamlining enables the clinician to prioritize these tasks in the evaluation. CONCLUSIONS: The delineation of those tasks depends on the time poststroke from enrollment to CIMT. This study demonstrates that the WMFT can be streamlined from 17 to 6 tasks.


Asunto(s)
Evaluación de la Discapacidad , Fuerza de la Mano/fisiología , Fuerza Muscular/fisiología , Debilidad Muscular/diagnóstico , Paresia/diagnóstico , Accidente Cerebrovascular/diagnóstico , Distribución por Edad , Terapia por Ejercicio/métodos , Femenino , Humanos , Masculino , Destreza Motora/fisiología , Debilidad Muscular/etiología , Debilidad Muscular/rehabilitación , Evaluación de Resultado en la Atención de Salud/métodos , Paresia/etiología , Paresia/rehabilitación , Valor Predictivo de las Pruebas , Psicometría/métodos , Recuperación de la Función/fisiología , Análisis de Regresión , Índice de Severidad de la Enfermedad , Distribución por Sexo , Accidente Cerebrovascular/complicaciones , Rehabilitación de Accidente Cerebrovascular , Análisis y Desempeño de Tareas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...